Fredag 14 Mars | 09:52:05 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-05 08:30 Bokslutskommuniké 2025
2025-11-13 08:30 Kvartalsrapport 2025-Q3
2025-08-21 08:30 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning EXPRS2 0.00 SEK
2025-05-28 N/A Årsstämma
2025-05-15 08:30 Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-10-30 - Split EXPRS2 40:1
2024-08-15 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 - Årsstämma
2024-05-16 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-03-23 - Extra Bolagsstämma 2023
2023-02-09 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-09-23 - Extra Bolagsstämma 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-07 - Bokslutskommuniké 2017
2017-11-30 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-01 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-04-19 - Extra Bolagsstämma 2017
2017-02-28 - Bokslutskommuniké 2016
2016-11-08 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion är ett bioteknikbolag fokuserat på utveckling av vacciner. Bolagets mål att bidra till hälso- och sjukvården genom att utveckla vacciner ämnade att stödja sjukdomsförebyggande och förbättra livskvaliteten globalt. ExpreS2ion använder sin ExpreS2™-teknologiplattform, som har validerats i kliniska fas III-studier, för utveckling och produktion av vaccinkomponenter. Bland pågående projekt utvecklar bolaget ES2B-C001, ett HER2-cVLP bröstcancervaccin som genomgår kliniska fas I-prövningar.
2021-12-22 08:30:00

Hørsholm, Denmark, December 22, 2021 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule. Additionally, anti-HER2 antibodies from these studies were found to effectively inhibit tumor growth in human cancer cells. The therapeutic vaccine is being developed towards first in human clinical trials in 2023.

The topline preclinical results reported today by ExpreS[2]ion are based on data from therapeutic studies in mice challenged intravenously and subcutaneously with HER2-positive breast cancer tumors. Two weeks after the inoculation of tumor cells, the first vaccine administrations were given. ES2B-C001 formulated in an adjuvant was found to totally block tumor development, whereas the control group progressively expanded with lung metastases and subcutaneously growing local tumors. Additionally, ES2B-C001 without adjuvant was found to inhibit, but not prevent, tumor development.

Furthermore, in vitro proof-of-concept studies have been conducted. These studies showed that when blood serum from vaccinated mice were applied to cultures of HER2-positive human breast cancer tumors, the growth was effectively inhibited. The inhibition indicates that the anti-HER2 antibodies mediate the arrest of tumor growth. When vaccine generated anti-HER2 antibodies in blood serum were applied in the same concentration as the conventional HER2-targeting monoclonal antibody, trastuzumab, tumor growth was inhibited to the same extent. Even in the case of using trastuzumab-resistant tumor cells, the vaccine generated anti-HER2 antibodies efficiently inhibited tumor growth.

CEO Bent Frandsen comments:        

"These excellent topline results from the ExpreS[2]ion-sponsored on-going preclinical trial confirm that the ES2B-C001 breast cancer vaccine has a strong therapeutic potential. It is also encouraging to see that it may fulfill the more specific unmet need for trastuzumab-resistant metastatic breast cancer patients. We remain on track to continue development towards a first in human trial in 2023."

Results from remaining on-going animal proof of concept studies are expected later in the first half of 2022. The vaccine project continues to be on path, with the start of the clinical program planned for 2022 with GMP manufacturing of ES2B-C001. This will be followed by, pending feedback from regulatory authorities, the start of a clinical Phase I safety and immune response study in 2023.

About ES2B-C001 and breast cancer

Breast cancer is a widespread oncology indication affecting more than 1.3 million people worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy Herceptin (trastuzumab) generates annual global sales of USD 7 billion. The target product profile of the HER2-cVLP breast cancer vaccine candidate is tailored to be highly competitive both in terms of cost and efficacy, thus aiming at a significant market share.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.